What Modafinil Mylan Treats: Main Uses and Benefits

Modafinil Mylan is considered relevant for addressing conditions characterized by chronic, excessive daytime sleepiness (EDS). It is applied across domains to address the challenging EDS associated with three primary disorders: narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS), and Shift Work Sleep Disorder (SWSD). A primary therapeutic benefit is sustained alertness, which offers supportive relief and helps patients cope more steadily with the functional strain linked to these conditions. The drug is used to help improve wakefulness associated with these specific indications.

The medication is relevant for managing symptoms of increased neurological or muscular activity, such as intense urges to sleep, sudden sleep attacks, and the resulting impaired vigilance that interfere with daily functioning. It is commonly used when residual sleepiness persists even with primary non-pharmacological therapies, such as Continuous Positive Airway Pressure (CPAP) for OSAHS, or in scenarios where symptoms of somnolence arise from required night or rotating shift schedules.

“This therapy may assist with maintaining functional stability during critical waking periods, contributing to easing the overall symptom load.”

---

Quick Fact: Relief for Excessive Daytime Sleepiness

Modafinil Mylan is considered a wakefulness-promoting agent used to support the management of symptoms that interfere with daily functioning, providing symptomatic assistance to help maintain functional stability.

Regulatory References

1. NIH DailyMed label information

Modafinil Mylan's eligibility is strictly defined by regulatory documents and limited to adult patients (aged 18 and over). The medicine is explicitly not recommended for the paediatric population (under 18 years) due to safety concerns and unestablished efficacy in this age group.

Absolute Contraindications:

• Known hypersensitivity to modafinil or armodafinil.
• Pre-existing cardiac conditions, specifically uncontrolled moderate to severe hypertension or cardiac arrhythmia.

Conditional and Restricted Use:

• Pregnancy Status: Use is contraindicated during pregnancy. Women of child-bearing potential must use effective non-hormonal contraception throughout treatment and for two months after discontinuation.
• Organ Function: Patients with severe hepatic impairment (liver disease) are subject to a mandatory dose reduction of half the usual amount. Caution is advised for those with severe renal impairment.
• Other Populations: Older adults and individuals with a history of certain psychiatric disorders (e.g., psychosis or mania) require close monitoring and conditional use as specified in official labeling.

Interactions with other medicines and products

The official interaction profile for modafinil is primarily defined by its effects on Cytochrome P450 (CYP) enzymes, leading to specific restrictions on co-administered medicines.

Interaction Type	Modafinil's Effect	Example Substrates Affected	Constraint / Outcome
CYP3A4/5 Induction	Moderate inducer of enzyme activity	Steroidal Contraceptives (Ethinyl Estradiol, Progestins), Triazolam, Midazolam, Cyclosporine	Decreased systemic exposure of co-administered drug; impaired contraceptive effectiveness is formally documented and requires alternative non-hormonal contraception.
CYP2C19 Inhibition	Reversible inhibitor of enzyme activity	Diazepam, Propranolol, Phenytoin, Omeprazole	Increased circulating levels and reduced clearance of the co-administered drug, potentially requiring dosage adjustment.

Modafinil also poses a risk of possible suppression of CYP2C9 activity. Consequently, regulatory documents advise regular monitoring of Prothrombin times during the first two months of use when co-administered with Anticoagulants such as Warfarin. Additionally, co-administration with potent CYP inducers (e.g., Carbamazepine) may reduce modafinil's own plasma levels. For non-drug interactions, regulatory labeling notes that food does not significantly affect the overall systemic exposure of modafinil, while the interaction with alcohol is officially unknown, leading to an advice for caution.

H2 — Dual Action on the Dopamine Transporter and Orexin System

Modafinil Mylan acts as a weak inhibitor of the Dopamine Transporter (DAT), which slows the removal of dopamine from the synaptic space and increases its concentration in the central nervous system (CNS). The drug also exerts an indirect influence on orexin (hypocretin) neurons located in the hypothalamus. The co-activation of these pathways is functionally associated with a less transient physiological arousal state, compared to mechanisms based solely on reuptake blockade.

H2 — Cascading Activation of Arousal Pathways

The activation of the orexin pathway triggers a broad signal across key brain regions, leading to the indirect enhancement of both histaminergic and noradrenergic (norepinephrine, NE) neurotransmission. Furthermore, the drug is associated with reduced inhibitory GABAergic signaling in arousal-regulating areas. This multi-system cascade results in the propagation of activity through circuits that regulate the sleep-wake cycle, contributing to the physiological state of sustained arousal.

H2 — Mechanistic Specificity and Physiological Constraints

The precise link between DAT inhibition and orexin activation remains an area of ongoing scientific investigation; thus, the full mechanism is not completely understood. The drug's action is dependent on the function of the dopamine and alpha1-adrenergic pathways for the expression of its primary physiological function. This selectivity also means the mechanism focuses primarily on arousal state stabilization, and therefore is not associated with the functional modulation of distinct neural pathways that regulate episodes of muscle atonia.

Official Administration Guidelines for Modafinil Mylan

Modafinil Mylan is administered exclusively by the oral route as a tablet that must be swallowed whole. The medicine can be taken with or without food, as its overall absorption is not significantly affected by meals.

---

Standard Dosing Regimen

The standardized adult regimen is 200 mg taken once daily. The specific timing of administration is tied to the condition being addressed:

Condition	Timing of Daily Dose
Narcolepsy & Obstructive Sleep Apnea	Once daily in the morning
Shift Work Disorder (SWD)	Approximately one hour before the start of the scheduled work shift

While 200 mg is the usual dose, the maximum daily dose described in official documentation is 400 mg. For some chronic conditions, the total daily amount may be administered in divided doses, taken in the morning and at noon. If a dose is missed, official instructions advise to skip the missed dose and resume the regular schedule, rather than doubling the subsequent dose.

---

Population-Specific Adjustments

Official labels mandate procedural adjustments to the standard regimen for specific groups:

• Severe Hepatic Impairment: The daily dosage must be reduced by half (e.g., 100 mg) to account for impaired drug clearance.
• Older Adults (Geriatric): A lower starting dose, such as 100 mg, is recommended due to potential age-related changes in clearance.
• Long-Term Use: For continuous administration, the necessity of the long-term regimen must be periodically re-evaluated by a healthcare professional, as long-term efficacy has not been systematically established.

Research Evidence

For Excessive Daytime Sleepiness Associated with Narcolepsy

Research examined Modafinil Mylan in studies involving individuals with conditions characterized by fluctuating or episodic manifestations, such as narcolepsy. These trials primarily monitored outcomes reflecting daily functioning or activity level and were applied in studies examining patient-reported experiences over defined time intervals. The research explored how symptoms change over time.

The findings indicate patterns related to outcomes capturing phases of heightened symptom activity, which were defined by the study as periods of increased sleepiness. Data show patterns related to objective measures used in the study, such as wakefulness latency tests. The studies report how symptoms evolved in the observed populations during the period Modafinil Mylan was evaluated in.

While research describes these short-term changes, certainty remains low regarding the full spectrum of long-term effects, as follow-up durations were limited in many studies. The evidence quality varies across studies, and the results apply only to the populations studied. Research provides context but not individual predictions; findings describe group patterns, not personal outcomes. Furthermore, evidence is limited regarding studies involving specific age groups, such as pediatric and geriatric populations.

For Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnoea/Hypopnea Syndrome (OSAHS)

Studies examined Modafinil Mylan in patients with Obstructive Sleep Apnoea/Hypopnea Syndrome (OSAHS) who also experience excessive sleepiness. These studies explored short-term symptom changes and were conducted in contexts involving fluctuating or unstable symptoms. Outcomes related to systemic or functional imbalance were monitored alongside patient-reported outcomes describing perceived discomfort.

Research examined Modafinil Mylan in studies that included standard treatments. Findings describe patterns related to measurements of patient-reported sleepiness taken during the study period. Research was applied in studies focusing on episodes where symptoms become more noticeable.

For Chronic Shift Work Sleep Disorder (SWSD)

Studies involving individuals with conditions associated with acute or disruptive episodes, such as Chronic Shift Work Sleep Disorder, explored Modafinil Mylan. Research examined temporary physiological imbalance resulting from working schedules that conflict with the body’s natural cycle. This was relevant in trials assessing short-term or episodic symptom patterns, specifically regarding outcomes reflecting daily functioning during scheduled work shifts.

The data show patterns related to patient-reported outcomes describing perceived discomfort or wakefulness when Modafinil Mylan was observed in studies focusing on performance during night shifts. The research describes patterns related to measurements taken during the study period, primarily concerning objective assessments of wakefulness during the work period.

Key Studies & References

1. FDA Label: PROVIGIL (modafinil) tablet - Detailed Information on Indications and Limitations (DailyMed)

Common questions about Modafinil Mylan (FAQ)

---

Q: Can women who are pregnant or breastfeeding use Modafinil Mylan?

A: Official product information states that the use of this medicine during pregnancy is generally contraindicated due to the documented potential for harm to the unborn baby. For women who are breastfeeding, regulatory documents indicate that the drug is excreted into human milk. Therefore, official guidance advises that use of the medicine during this period requires careful consideration.

---

Q: What are the long-term safety concerns associated with taking Modafinil Mylan?

A: The effectiveness and safety of the medicine have not been systematically evaluated in long-term controlled clinical trials beyond limited short-term study periods. Official guidelines indicate that the necessity for continued use of the long-term regimen should be periodically re-evaluated by a healthcare professional. This is due to the lack of systematically established long-term efficacy and safety data.

---

Q: What is the difference between Modafinil and Armodafinil?

A: Modafinil is chemically defined as a racemic mixture, which means it contains two active forms called R- and S-enantiomers. In contrast, Armodafinil is composed of only the R-enantiomer of the drug. Both substances are related, to the extent that an allergy to one is a contraindication for the other.

---

Q: What should I do if I experience an unusual or severe reaction?

A: Regulatory guidance describes the specific serious reactions for which immediate medical help is warranted. These include a severe rash, swelling, mouth sores, fever, or the emergence of new or worsening psychiatric symptoms, and indicate the medicine should be stopped when they occur. Prompt reporting of such reactions to a medical professional is described as crucial.

---

Q: What does the research say about Modafinil Mylan's potential for misuse?

A: Modafinil is classified by regulatory bodies as a Schedule IV controlled substance. This official designation is based on clinical and regulatory assessments indicating that the medicine carries a potential for abuse and dependence.

---

Q: Are allergic reactions to Modafinil Mylan common?

A: Official safety information indicates that serious allergic skin reactions, such as Stevens-Johnson Syndrome, are considered rare events but have been reported. Less severe skin reactions, including general rash and itching, are classified as uncommon adverse effects in the product labeling.

---

Q: What is the average duration of action for a single dose?

A: According to the clinical pharmacology data, the half-life of modafinil is approximately 15 hours. The half-life is the time required for the amount of drug in the body to be reduced by half. This extended duration contributes to the medicine's ability to promote sustained wakefulness throughout the day.

---

Q: Is it safe to drive or operate machinery while taking Modafinil Mylan?

A: Official guidance includes cautions that driving or operating heavy machinery should be avoided. This is standard guidance until an individual understands how the medicine affects their personal level of wakefulness and alertness.

---

Q: Does Modafinil Mylan interact with common over-the-counter pain relievers?

A: The official drug labeling includes information on how the medicine interacts with various other substances. For a common over-the-counter pain reliever like acetaminophen, regulatory information generally indicates that no clinically significant interaction is expected.

---

Q: What are the signs of taking too much Modafinil Mylan?

A: Regulatory and public health information describes symptoms that may occur if too much of the medicine is taken. These signs can include agitation, confusion, or excitement, as well as an increased heart rate, fast or pounding heartbeat, and elevated blood pressure. Other effects may involve trouble sleeping, nausea, and diarrhea.

---

Q: Is it possible to develop a tolerance to Modafinil Mylan over time?

A: Clinical research studies examining the drug for approved uses have explored the potential for tolerance. Official reports indicate that clinical trials lasting for a period of up to 40 weeks generally showed no evidence that pharmacological tolerance developed during continuous treatment.

---

Q: What information is available regarding stopping Modafinil Mylan?

A: The medicine carries a potential for abuse and dependence. If the medicine is stopped abruptly, official sources note that it can result in symptoms such as lethargy, extreme sleepiness, or low mood. The process for discontinuing the medication is subject to the guidance of a healthcare professional.

---

Q: What is the 'Modafinil Mylan' tablet size or appearance?

A: Modafinil is supplied as an oral tablet in specific available strengths, such as 100 mg and 200 mg. The specific color, shape, and imprint of the tablets are unique to the Mylan product and are detailed within the official product documentation.

---

Q: What is the purpose of the boxed warning, if one exists?

A: The official regulatory label uses specific formatting to highlight the most serious safety warnings. These warnings focus on the risk of severe rash, including conditions like Stevens-Johnson Syndrome, as well as the risk of serious psychiatric problems.

---

Q: Can Modafinil Mylan be taken with antidepressants or anxiety medications?

A: Official labeling states that Modafinil Mylan can influence the way the body processes other medicines by affecting liver enzymes. This interaction may lead to increased circulating levels of certain anxiety medications (such as Diazepam) and some types of antidepressants.

Storage and Protection Requirements

Modafinil tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The regulatory labeling mandates keeping the medicine in a closed, tightly closed container and protecting it from environmental extremes. This includes storing the product away from excessive heat, moisture, and direct light, and ensuring it is kept from freezing.

Child Safety and Controlled Substance Storage

The medication must be stored out of the reach of children. Due to its classification as a Schedule IV controlled substance, official guidance also requires the medicine to be stored in a safe place to help prevent misuse.

Official Disposal Instructions

Unused or expired Modafinil Mylan must be disposed of according to regulatory requirements. Patients are directed to ask a healthcare professional how to dispose of any medicine you do not use. The preferred method for discarding the medication is through a drug take-back program where available, in compliance with local waste disposal requirements.